_0.jpg)
Programme
|
Updated 30 May 2011 Pre-Conference Activities and Meetings |
|
| For further information about pre-conference activities and meetings during the conference, please click here | |
| 8 June 2011 | |
| 15:00-16:30 | Satellite Symposium - Pharmaxis - Updated Programme |
| 17:00-18:00 | ECFS Annual General Meeting |
| 18:30-21:30 | Opening Ceremony | Welcome Reception |
| 9 June 2011 | |
| 07:15-08:15 | Round Tables |
| 08:30-10:00 | Symposium 1 - Genes and Phenotype Moderators: S. Gallati (CH) / G. Cutting (US) |
| 08:30-09:52 | The CFTR2 project, impact in CF diagnosis - P. Sosnay (US) |
| 08:52-09:14 | Is ENaC a Modifier Gene? – H. Cuppens (BE) |
| 09:14-09:36 | Genes other than CFTR-Are they important? - B. Tümmler (DE) |
| 09:36-10:00 | A8.1 Haplotype: a Genetic Modifier in CF – H Corvol (FR) |
| 08:30-10:00 | Symposium 2 - Maximizing the Value of Registry Data in Europe |
| Moderators: M. Stern (DE) / R. Smyth (UK) | |
| 08:30-08:52 | Overcoming Disparities in CF Care in Europe; a Call for Political Action – A. Mehta (UK) |
| 08:52-09:14 | Impact of socio-economic deprivation on outcomes – A. Fogarty (UK) |
| 09.14-09.36 | Using registry data in daily care to improve outcome – M. Stern (DE) |
| 09:36-10:00 | Will Auxometric Data Help Us in Evaluating the Nutritional Status of CF Patients? - L. Viviani (IT) |
| 08:30-10:00 | Symposium 3 - Laboratory Diagnostics- Why bother? |
| Moderators: M. Denton (UK) / R. Cantón (ES) | |
| 08:30-08:52 | Overview: History till Today- J. Govan (UK) |
| 08:52-09:14 | The Role of Culture Independent Identification Methods in CF Microbiology – R. Cantón (ES) |
| 09:14-09:36 | Typing: Which Method and When You Should Do it – T. Kidd (AU) |
| 09:36-10:00 | Do We Still Need Susceptibility Testing in CF? – J. Foweraker (UK) |
| 08:30-10:00 | Symposium 4 - Pharmacoeconomics of CF in European Countries |
| Moderators: A. Reimann (DE) / I. Fajac (FR) | |
| 08:30-08:40 | Introduction - K. De Boeck (BE) |
| 08:40-09:02 | Introducing new drugs into the European market: view of industry – |
| 09:02-09:24 | Introducing new drugs into the European market: View of Regulatory affairs – I. Eichler (EU) |
| 09:24-09:46 | Introducing new drugs into the European market: View of the patient associations – A. Reimann (DE) |
| 09:46-10:00 | Panel discussion |
| 08:30-10:00 | Symposium 5 - Psychological Interventions |
| Moderators: J. Abbott (UK) / L. Goldbeck (DE) | |
| 08:30-08:52 | An Overview of Psychological Interventions in CF – M. Bryon (UK) |
| 08:52-09:14 | Interventions for Improving Eating Behaviour in Children with CF – L. Stark (US) |
| 09:14-09:36 | Development of Guidelines for Patient Education - D. Staab (DE) |
| 09:36-10:00 | Motivational Interviewing – G. Latchford (UK) |
| 08:30-10:00 | Symposium 6 - Pathogenesis of Early Inflammation in CF |
| Moderators: S. Randell (US) / M. Amaral (PT) | |
| 08:30-08:52 | Evidence from Cell Biology – S. Randell (US) |
| 08:52-09:14 | Evidence from Small Animal Models – B. Scholte (NL) |
| 09:14-09:36 | Evidence from Large Animal Models: J. Engelhardt (US) |
| 09:36-10:00 | Evidence from Patients – D. Hartl (DE) |
| 10:00-10:30 | Coffee Break |
| 10:30-12:00 | Symposium 7 - Making Sense of Metagenomics |
| Moderators: P. Murphy (IE) / G. Döring (DE) | |
| 10:30-10:52 | Microbial Diversity in the CF Lung – S. Lynch (US) |
| 10:52-11:14 | New Bacteria Invaders: Should we be worried? – M. Denton (UK) |
| 11:14-11:36 | Pro: Anaerobes matter – G. Döring (DE) |
| 11:36-12:00 | Con: Anaerobes don’t matter – S. Bell (AU) |
| 10:30-12:00 | Symposium 8 - Nutrition and Inflammation |
| Moderators: B. Strandvik (SE) / HJ Verkade (NL) | |
| 10:30-10:52 | Can Dietary Changes in Fat improve Inflammatory Status - B. Strandvik (SE) |
| 10:52-11:14 | Antioxidants and CF with focus on their anti-inflammatory effect – H.K. Biesalski (DE) |
| 11:14-11:36 | Milk Phospholipids and Sphingomyelin – Are they anti-inflammatory? – Å. Nilsson (SE) |
| 11:36-12:00 | Ghrelin and CF – A. Floto (UK) |
| 10:30-12:00 | Symposium 9 - CFTR Structure, Function and Therapy |
| Moderators: U. Seidler (DE) / H. De Jonge (NL) | |
| 10:30-10:52 | CFTR Protein from Structure to Therapy – B. Ford (UK) |
| 10:52-11:14 | ATP-Dependent Conformational Changes of the NBDs – O. Moran (IT) |
| 11:14-11:36 | Structural Domains of CFTR Involved in Channel Gating - P. Vergani (UK) |
| 11:36-12:00 | CFTR Drug-Binding Sites – D. Sheppard (UK) |
| 10:30-12:00 | Symposium 10 - Clinical Trials in Young Children with CF - Investing in the Future |
| Moderators: A. Smyth (UK) / K. De Boeck (BE) | |
| 10:30-10:52 | Challenges and Solutions for Clinical Trials in Young Children – K. De Boeck (BE) |
| 10:52-11:14 | Keeping the Lungs Pristine – Mucus Clearance Drugs – F. Ratjen (CA) |
| 11:14-11:36 | Keeping the Lungs Pristine - Antibiotics - C. Wainwright (AU) |
| 11:36-12:00 | Physiotherapy Trials in Young Children - Untapped Potential? – E. Main (UK) |
| 10:30-12:00 | Symposium 11 - Grand Rounds in Pulmonary Disease |
| Moderators / Expert panel: H. Heijermann (NL) / E. Rietschel (DE) / D. Bilton (UK) | |
| 10:30-10:45 | P.aeruginosa Persists in the Upper Airways After Lung Transplantation – J. Mainz (DE) |
| 10:45-11:00 | Continuous Colistin Inhalation Therapy in a CF Patient with Colistin Allergy after Drug-Desensitization – S. Renner (AT) |
| 11:00-11:15 | Cystic Fibrosis Fungal Lung Disease: A Diagnostic Dilemma – K. Hurt (UK) |
| 11:15-11:30 | Can Cystic Fibrosis Present Atypically as Hypereosinophilic Syndrome? – C. Ohri (UK) |
| 11:30-11:45 | A Pain in the Neck – K. Williams (UK) |
| 11:45-12:00 | Treatment Dilemmas of Aspergillosis in Very Young Patient – A. Hollsing (SE) |
| Expert panel sum up and Best Case Presentation Award | |
| 10:30-12:00 | Special Session - From Clinical Research to Clinical Practice |
| Moderators: S. Madge (UK) / J. Bradley (UK) | |
| 10:30-10:52 | The Clinical Research Co-ordinator, what Does this Involve? - E van der Wiel - Kooij (NL) |
| 10:52-11:14 | Optimising Recruitment into Clinical Trials – J. Bradley (UK) |
| 11:14-11:36 | Running an Investigator Lead Study – A. Quittner (US) |
| 11:36-12:00 | How to Translate Research into Practice – P. Flume ( US) |
| 12:30-14:00 | Satellite Symposium - Johns Hopkins University School of Medicine - Programme |
| 12:30-14:00 | Satellite Symposium - Gilead - Programme |
| 12:30-14:00 | Satellite Symposium - Roche - Programme |
| 14:00-15:00 | Guided Poster Tours: - Gastrointestinal/Liver Disease/Nutrition/Metabolic Complications of CF - Microbiology |
| 14:00-15:00 |
Posters for Discussion: |
| 15:00-16:30 | Workshop 1 - Psychosocial - Growing up with CF - Adolescents and Young Adults |
| Moderators: T. Havermans (BE) / M. Butler (UK) | |
| 15:00-15:10 | Introduction – T. Havermans (BE) |
| 15:10-15:25 | Abstract 350: Parenting adolescents with cystic fibrosis: An interpretive description of the adolescent point of view – V. Bregnballe (DK) |
| 15:25-15:40 | Abstract 330: Factors predicting outcome in adolescents with cystic fibrosis (CF) after transition to adult care – H. Pasterkamp (CA) |
| 15:40-15:55 | Abstract 331: The German multimodal project “fit for life” to optimize the CF-course in children with critical trends - regarding the subject physical activity – C. Moos-Thiele (DE) |
| 15:55-16:10 | Abstract 345: Decision making in young adults with CF about risk of infection: A Vignette Study – G. Latchford (UK) |
| 16:10-16:25 | Abstract 347: Communication and information about Reproductive and Sexual Health in Cystic Fibrosis: A Review – T. Havermans (BE) |
| 16:25-16:30 | Wrap up |
| 15:00-16:30 | Workshop 2 - Ion Transport and ASL |
| Moderators: L. Galietta (IT) / D. Sheppard (UK) | |
| 15:00-15:15 | Calcium-activated Chloride Channels - L. Galietta (IT) |
| 15:15-15:30 | TMEM16 Proteins as Compensatory Anion Channels in CF- K. Kunzelmann (DE) |
| 15:30-15:45 | Abstract 50: Low Temperature and Chemical Rescue Affect the Molecular Proximity of DF508- CFTR and ENaC – B. Berdiev (US) |
| 15:45-16:00 | Abstract 64: Correction of ∆F508-CFTR in Human Airway Epithelia and Ex Vivo Rectal Biopsies by S-CIS-LOCKED BITHIAZOLE Corrector-29 – N. Derichs (DE) |
| 16:00-16:15 | Abstract 67: Preclinical evaluation of preventive hypertonic saline therapy for cystic fibrosis-like lung disease in mice – Z. Zhou (DE) |
| 16:15-16:30 | Abstract 272: Ursodeoxycholate Reduces Cholate Biosynthesis Rate And Pool Size In Cftr-/- Mice – F. Bodewes (NL) |
| 15:00-16:30 | Workshop 3 - Nutritional Issues before and after Transplantation |
| Moderators: B. Assael (IT) / C. Haworth (UK) | |
| 15:00-15:15 | Nutritional support prior to and following lung transplantation – D. Kalnins (CA) |
| 15:15-15:30 | Psychological aspects of nutrition in severe disease– S. Perobelli (IT) |
| 15:30-15:45 | Abstract 312: New Onset Diabetes after Lung Transplantation in Patients with Cystic Fibrosis Compared with Patients Suffering from other Lung Diseases – G. Van Meerkerk (NL) |
| 15:45:16:00 | Abstract 306: Interaction of Fat-soluble Vitamins with Immunosuppressant Drugs in Lung Transplanted CF Patients – L. Hjelte (SE) |
| 16:00-16:15 | Abstract 285: The Impact of BMI on Survival of Patients with Cystic Fibrosis Undergoing Lung Transplantation: A Single Centre Experience – K. Hester (UK) |
| 16:15-16:30 | Abstract 277: Outcome Following Lung Transplantation for Patients With Cystic Fibrosis Related Liver Disease: A Single Centre Experience – S. Wiscombe (UK) |
| 15:00-16:30 | Workshop 4 - Registries and Clinical Outcomes |
| Moderators: H. Olesen (DK) / T. Wagner (DE) | |
| 15:00-15:20 | Using Registry Data for Clinical Research – H. Olesen (DK) |
| 15:20-15:40 | Abstract 41: Who should be analyzed in a CF registry? – M. Thomas (BE) |
| 15:40-15:55 | Abstract 194: Understanding the Natural Progression in FEV1 Decline in Patients with Cystic Fibrosis – D. Taylor-Robinson (UK) |
| 15:55-16:10 | Abstract 274: Recurrent pancreatitis among CF patients at Stockholm CF Centre. Correlations with genotype – F. Karpati (SE) |
| 16:10-16:30 | Abstract 370: Increasing incidence of cystic fibrosis being diagnosed in adulthood over time: An analysis of two decades of care – M. Weir (UK) |
| 15:00-16:30 | Workshop 5 - Translational Research in CF |
| Moderators: P. Campbell (US) / F. Dufour (FR) | |
| 15:00-15:20 | CF Research – Challenges for the next 5 years? – P. Campbell (US) |
| 15:20-15:34 | Abstract 61: VX-770 in Subjects with Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation – P. Flume (US) |
| 15:34-15:48 | Abstract 62: Investigational Compound VX-770 Potentiated Multiple CFTR Channel Gating Mutants In Vitro – F. Van Goor (US) |
| 15:48-16:02 | Abstract 81: Inhaled L-arginine in patients with cystic fibrosis – a randomized controlled trial – H. Grasemann (CA) |
| 16:02-16:16 | Abstract 77: Phase III Study [CF-302] of Inhaled Dry Powder Mannitol (Bronchitol™) in Cystic Fibrosis – Results from the 6 month Open Label Phase – M. Aitken (US) |
| 16:16-16:30 | Abstract 80: A Randomised, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with Cystic Fibrosis – S. Elborn (UK) |
| 15:00-16:30 | Oral Poster Session 1 - CF Lung Disease Outcomes and Biomarkers |
| Moderators: S. Bell (AU) / C. Goss (US) | |
| 15:00-15:10 | Abstract 201: Reversibility Of Trapped Air On CT Scans Of CF Patients, An Automated Approach – M. Loeve (NL) |
| 15:10-15:20 | Abstract 227: CT Scores Correlate With Survival In CF Patients awaiting Lung Transplantation – M. Loeve (NL) |
| 15:20-15:30 | Abstract 191: Magnetic resonance imaging (MRI) as a non-invasive, radiation-free imaging modality to study the onset and progression of lung disease in infants and young children with cystic fibrosis – E. Fritzsching (DE) |
| 15:30-15:40 | Abstract 211: Lung Clearance Index (LCI) as a tool to assess the effect of antibiotics among pre-schoolers with CF – E. Hatziagorou (GR) |
| 15:40-15:50 | Abstract 207: Recovery of Lung Function after Intensive Treatment due to Pulmonary Exacerbation in Children with Cystic Fibrosis – R. Kraemer (CH) |
| 15:50-16:00 | Abstract 187: Nitrous Oxide Production in Sputum from Cystic Fibrosis Patients with Chronic P. aeruginosa Lung Infection – M. Kolpen (DK) |
| 16:00-16:10 | Clinical Evaluation of VR496: A Novel, Dry Powder Heparin Formulation Delivered by Oral Inhalation in Patients with Cystic Fibrosis - D. Shale (UK) |
| 16:10-16:20 | Abstract 178: Assessment of Pulmonary Inflammation in Cystic Fibrosis Patients by Calprotectin Determination in Induced Sputum – M. Ruiz De Valbuena (ES) |
| 16:20-16:30 | Abstract 181: Development of a Novel Tool for the Rapid Detection of Neutrophil Elastase as a Marker of Inflammation within the Clinic – L. Martin (UK) |
| 16:30-17:00 | Coffee Break |
| 17:00-18:30 | Workshop 6 - Genetics/Screening - CFTR Genotypes and Phenotypes |
| Moderators: H. Cuppens (BE) / C. Férec (FR) | |
| 17:00-17:15 | Abstract 5: Assessing the impact of unclassified variants on splicing of CFTR mRNA: in silico predictions vs ex vivo assays – C. Raynal (FR) |
| 17:15-17:30 | Abstract 1: Comparison of bioinformatics, reporter minigene and mRNA study to analyse the effect of unclassified variants on CFTR mRNA splicing – M.P. Audrezet (FR) |
| 17:30-17:45 | Abstract 16: Negative Impact of F508del on the Effect of the CFTR – S. Gallati (CH) |
| 17:45-18:00 | Abstract 17: Does the CFTR/ENaC genotype predispose to cystic fibrosis? – A. Norek (PL) |
| 18:00-18:15 | Abstract 9: Atypical CFTR Variants Impact Pancreatitis and Male Infertility in the North American Pancreatitis Study – J. LaRusch (US) |
| 18:15-18:30 | Abstract 12: The relation between Meconium Ileus Prevalence Score and functional severity of CFTR mutations – T. Gonska (CA) |
| 17:00-18:30 | Workshop 7 - Infection Control: Challenges from Transmissible Organisms |
| Moderators: N. Høiby (DK) / I. Balfour-Lynn (UK) | |
| 17:00-17:15 | Overview: Optimal Clinic design – P. Murphy (IE) |
| 17:15-17:30 | Abstract 160: Acquisition of methicillin-resistant Staphylococcus aureus (MRSA ) by patients with CF: risk factors and impact on outcome – L. De Meirleir (BE) |
| 17:30-17:45 | Abstract 133: Characteristics and susceptibilities of MRSA in Paediatric CF patients in USA – M. Muhlebach (US) |
| 17:45-18:00 | Abstract 129: Comparison of Clinical and Environmental Pseudomonas aeruginosa: Evidence for Recombination – T. Kidd (AUS) |
| 18:00-18:15 | Abstract 137: The End of Long-Term Outbreak with Highly Transmissible Burkholderia cenocepacia ST32 – K. Dedeckova (CZ) |
| 18:15-18:30 | Abstract 149: 2009 H1N1 Influenza A in Cystic Fibrosis patients. A French collaborative study – J. Bucher (FR) |
| 17:00-18:30 | Workshop 8 - Physiotherapy - Exercise in CF |
| Moderators: | |
| 17:00-17:15 | Abstract 255: Habitual physical activity in children with CF: Reliability and relationship with quality of life and lung function – L. Kent (UK) |
| 17:15-17:30 | Abstract 250: Field Tests to Assess Exercise Capacity in CF Children – C. Cazzarolli (IT) |
| 17:30-17:45 | Abstract 253: Exercise physiologic response during three different video games in cystic fibrosis patients – T. del Corral Núñez-Flores (ES) |
| 17:45-18:00 | Abstract 252: Correlation of physical performance and quality of life in adult patients with cystic fibrosis – M. Hofer (CH) |
| 18:00-18:15 | Abstract 248: Using an Individualized Treadmill Protocol to Assess Maximal Steady State Exercise Capacity in CF – A. Morris (UK) |
| 18:15-18:30 | Abstract 231: Respiratory muscle function in patients with Cystic Fibrosis – T. Dassios (GR) |
| 17:00-18:30 | Workshop 9 - Innate Immunity |
| Moderators: B. Plant (IE) / D. Hartl (DE) | |
| 17:00-17:20 | Overview: Impaired Innate immunity in CF – D. Hartl (DE) |
| 17:20-17:34 | Abstract 171: The Chitinase-like Protein YKL-40 modulates Cystic Fibrosis Lung Disease – A. Hector (DE) |
| 17:34-17:48 | Abstract 169: Bactericidal activity of human CF macrophages against Pseudomonas aeruginosa – N. Cifani (IT) |
| 17:48-18:02 | Abstract 166: Role of Pseudomonas aeruginosa flagellin in airway mucin production: relevance for cystic fibrosis disease – F. BenMohamed (FR) |
| 18:02-18:16 | Abstract 174: Hypoxia Amplifies NF-kappaB Dependent Signaling in Response to Pseudomonas Aeruginosa and Prevents Internalisation in Pulmonary Epithelial Cells – K. Schaffer (IE) |
| 18:16-18:30 | Abstract 185: Variability of Toll like receptor mediated innate immune response in patients with cystic fibrosis and their relationship with clinical phenotype – O. O’Connell (IE) |
| 17:00-18:30 | Workshop 10 - Nursing - Psychosocial Consequences of Newborn Screening |
| Moderators: J. Dankert-Roelse (NL) / L. Semple (CA) | |
| 17:00-17:22 | Overview of Psychosocial Issues Surrounding Newborn Screening – L. Semple (CA) |
| 17:22-17:37 | Abstract 366: Cystic Fibrosis Newborn Screening: Facilitating Family Centred Care – L. Fairservice (CA) |
| 17:37-17:52 | Abstract 39: Processing of Carrier Results Following Newborn Screening for Cystic Fibrosis: Experiences from a UK Region – R. Trinick (UK) |
| 17:52-18:07 | Abstract 44: Difficult Counseling Situations – Lessons From a CF Expertise Laboratory – M. Poulou (GR) |
| 18:07-18:22 | Abstract 42: Do false positive test results for newborn screening for cystic fibrosis lead to long term parental anxiety? – A. Vernooij-van Langen (NL) |
| 18:22-18:30 | Sum Up |
| 17:00-18:30 | Workshop 11 - Cystic Fibrosis Related Diabetes |
| Moderators: M. Ballmann (DE) / B. Assael (IT) | |
| 17:00-17:15 | Abstract 316: Cardiac autonomic neuropathy (CAN) is related to lung function in adults with cystic fibrosis related diabetes (CFRD) – R. Rashid (UK) |
| 17:15-17:30 | Abstract 315: Cardiac autonomic neuropathy (CAN) is more likely to occur in Cystic fibrosis (CF) patients with or without diabetes than in patients with Type 1 diabetes (T1DM) – R. Rashid (UK) |
| 17:30-17:45 | Abstract 314: Occurrence of Microalbuminuria in Cystic Fibrosis-Related Diabetes (CFRD) and Its Clinical Significance – M. Haris (UK) |
| 17:45-18:00 | Abstract 313: An audit of long term complication screening for Cystic Fibrosis Related Diabetes: The ticking time bomb! – P. Dyce (UK) |
| 18:00-18:15 | Abstract 311: Gender Differences in Insulin Levels in a large cohort of non-diabetic Cystic Fibrosis patients – L. Belson (CA) |
| 18:15-18:30 | Abstract 368: Aetiology of Erectile Dysfunction in Cystic Fibrosis – S. Henman (UK) |
| 19:00-20:30 | Satellite Symposium - Pari - Programme |
| 10 June 2011 | |
| 07:15-08:15 | Round Tables |
| 07:15-08:15 | Satellite Symposium - Abbott - Programme |
| 08:30-10:00 | Symposium 12 - Pipeline Update |
| Moderators: P. Flume (US) / H. Tiddens (NL) | |
| 08:30-08:52 | Gene Therapy - Single Dose to Multidose – E. Alton (UK) |
| 08:52-09:14 | Enhancing CFTR function – I. Fajac (FR) |
| 09:14-09:36 | Improving mucociliary clearance – S. Donaldson (US) |
| 09:36-10:00 | Targeting micro Organisms – P. Flume (US) |
| 08:30-10:00 | Symposium 13 - Bicarbonate and Mucus in CF |
| Moderators: M. Gray (UK) / M. Hug (DE) | |
| 08:30-08:52 | Introduction: Principles of Bicarbonate Secretion – M. Gray (UK) |
| 08:52-09:14 | Regulation of CFTR Bicarbonate Conductance by Kinases – M.-G. Lee (KR) |
| 09:14-09:36 | Defective Bicarbonate Secretion in CF Intestine – U. Seidler (DE) |
| 09:36-10:00 | Bicarbonate Transport and Mucus Secretion. What's the Role of CFTR? – P. Quinton (US) |
| 08:30-10:00 | Symposium 14 - The CF Lung and the Environment |
| Moderators: S. Elborn (UK) / G. Cutting (US) | |
| 08:30-08:52 | Risk Factors for Environmental Acquisition of Micro-Organisms – J. Moore (UK) |
| 08:52-09:14 | Exposure to Aeroallergens – R. Moss (US) |
| 09:14-09:36 | Effects of Air Pollution – C. Goss (US) |
| 09:36-10:00 | Occupational Hazards for the CF Lung– B. Nemery (BE) |
| 08:30-10:00 | Symposium 15 - Implication of Exercise |
| Moderators: J. Zerlik (DE) / B. Arets (NL) | |
| 08:30-08:52 | How does Exercise Affect CF Airways at the Cellular Level – H. Hebestreit (DE) |
| 08:52-09:14 | Implications of Exercise Research on Clinical Practice – L. Morrison (UK) |
| 09:14-09:36 | Exercise for Airway Clearance – T. Dwyer (AU) |
| 09:36-10:00 | Exercising the CF patient with Co-morbidities – C. Gallagher (IE) |
| 08:30-10:00 | Symposium 16 - Intestinal Inflammation |
| Moderators: J. Walkowiak (PL) / A. Munck (FR) | |
| 08:30-08:52 | What We Can Learn From the Intestine in the Mouse Model – L. Clarke (US) |
| 08:52-09:14 | What we can learn from the intestine in the CF Pig model – A. Uc (US) |
| 09:14-09:36 | Evidence for intestinal inflammation in CF – M. Wilschanski (IL) |
| 09:36-10:00 | European Guidelines on Diagnosis and Treatment of DIOS – C. Colombo (IT) |
| 10:00-10:30 | Coffee Break |
| 10:30-12:00 | Symposium 17 - Current Challenges in Diagnostics |
| Moderators: M. Stuhrmann (DE) / E. Girodon (FR) | |
| 10:30-10:52 | CFTR Rearrangements in Europe – E. Girodon (FR) |
| 10:52-11:14 | Immigration from non EU Countries: How Does it Affect Screening? – J. Dankert-Roelse (NL) |
| 11:14-11:36 | Newborn Screening in Europe: Difficulties in Implementation – O. Sommerburg (DE) |
| 11:36-12:00 | CF Related Diseases: Diagnostic Dilemmas – M. Wilschanski (IL) |
| 10:30-12:00 | Symposium 18 - Proteases and Lung Disease |
| Moderators: M. Gentzsch (US) / C. Taggart (UK) | |
| 10:30-10:52 | Proteases and Ion Transport Regulation – M. Gentzsch (US) |
| 10:52-11:14 | Proteases and Mucin Regulation – J. Voynow (US) |
| 11:14-11:36 | Proteases and Tissue Remodelling – A. Belaaouaj (FR) |
| 11:36-12:00 | Proteases and Innate Immunity – C. Taggart (UK) |
| 10:30-12:00 | Symposium 19 - Interaction of Other Systems with Lung Disease |
| Moderators: C. Haworth (UK) / M. Cipolli (IT) | |
| 10:30-10:52 | Heart- Pulmonary Hypertension and Right Heart Failure - I. Balfour-Lynn (UK) |
| 10:52-11:14 | Implications of Severe Renal Disease – M. Walshaw (UK) |
| 11:14-11:36 | GI System – Gastro-esophageal Reflux – L. Dupont (BE) |
| 11:36-12:00 | Reproductive System – Pregnancy and Contraception – B. Plant (IE) |
| 10:30-12:00 | Symposium 20 - Clinical trials of Inhaled Therapy - What Microbiological Endpoints Tell You |
| Moderators: R. Cantón (ES) / F. Ratjen (CA) | |
| 10:30-10:52 | Quantitative Microbiology - Is it Relevant? - N. Høiby (DK) |
| 10:52-11:14 | Antimicrobial Resistance Mechanisms in CF Bacteria – S. Haüssler (DE) |
| 11:14-11:36 | Antimicrobial Resistance - Does it Matter? - A. Smith (US) |
| 11:36-12:00 | Choosing the correct antibiotic for individual patients - M. Parkins (CA) |
| 10:30-12:00 | Symposium 21 - Mental Health |
| Moderators: G. Ullrich (DE) / C. Becher (CH) | |
| 10:30-10:52 | Disordered Eating and Body Image – N. Brager (CA) |
| 10:52-11:14 | TIDES - Clinical Implications – L. Goldbeck (DE) |
| 11:14-11:36 | Suicide and Self Harm – A. Duff (UK) |
| 11:36-12:00 | Strategies for Improving Mental Health – M. Kirszenbaum (FR) |
| 10:30-12:00 | Oral Poster Session 2 - Optimising CF Center Care |
| Moderators: H. Tiddens (NL) / S. Madge (UK) | |
| 10:30-10:40 | Abstract 334: Attitudes and Barriers to the Implementation of New Ehealth Strategies in CF – J. Wilson (AU) |
| 10:40-10:50 | Abstract 376: The role of electronic patient records (EPR) in improving service efficiency and clinical performance in a Regional Adult UK Centre – C. Etherington (UK) |
| 10:50-11:00 | Abstract 329: Effects Of Clinical Variables And Social Status On Clinic Defaulting In Adult CF (Cystic Fibrosis) Patients – D. Nazareth (UK) |
| 11:00-11:10 | Abstract 337: The German multimodal project “fit for life” to optimize the CF-course in children with critical trends: first results regarding the initial 12 months period – N. Niemann (DE) |
| 11:10-11:20 | Abstract 258: The Development of a Musculoskeletal Screening Tool for Adults with Cystic Fibrosis – J. Ashbrook (UK) |
| 11:20-11:30 | Abstract 326: Incidence and resource utilisation of pulmonary exacerbations (PE) in patients with CF in the UK – J. Bradley (UK) |
| 11:30-11:40 | Abstract 346: Health Related Quality of Life (HRQoL) and Health Utility In Patients With CF and Chronic Pseudomonas aeruginosa (PA) infection In The UK – J. Bradley (UK) |
| 11:40-11:50 | Abstract 354: Associations between treatment non-adherence and beliefs about medicines in cystic fibrosis – J. Abbott (UK) |
| 11:50-12:00 | Abstract 332: Validation of the Treatment Satisfaction Questionnaire for Medication (TSQM) in Cystic Fibrosis (CF) – A. Regnault (CH) |
| 12:30-14:00 | Satellite Symposium - Novartis - Programme |
| 14:00-15:00 | Guided Poster Tours: - Screening / Diagnosis / Genetics - Psychosocial Issues / Nursing / Delivery of Care - Physiotherapy |
| 14:00-15:00 | Posters for Discussion: - Genetics - Screening & Diagnosis - CFTR/Cell Biology/Cell Physiology - Physiotherapy - Delivery of Care - Nursing & Psychosocial Issues - Epidemiology / Registry - Other Issues |
| 15:00-16:30 | Workshop 12 - Immunological Reactions to Fungal Micro-Organisms |
| Moderators: R. Moss (US) / G. Taccetti (IT) | |
| 15:00-15:22 | Do’s and Don’t’s in the Management of ABPA – R. Moss (US) |
| 15:22-15:39 | Abstract 229: Clinical relevance of Aspergillus in cystic fibrosis patients sensitized to Aspergillus – O. Eickmeier (DE) |
| 15:39-15:56 | Abstract 184: Basophil CD203c as a potential clinically relevant biomarker in Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis – R. Moss (US) |
| 15:56-18:13 | Abstract 93: Aspergillus Bronchitis and ABPA in CF, A Spectrum of Disease Responding to Antifungal Therapy – N. Verma (UK) |
| 18:13-18:30 | Abstract 114: Aspergillus fumigatus susceptibility to itraconazole in adult patients with cystic fibrosis – P.-R. Burgel (FR) |
| 15:00-16:30 | Workshop 13 - New Challenges in Nutrition |
| Moderators: L. Hjelte (SE) / H. Watson (UK) | |
| 15:00-15:15 | What is Known about Vitamin D and CF - L. Hjelte (SE) |
| 15:15-15:30 | Is there a Place for Bisphophanates in CF? - C. Haworth (UK) |
| 15:30-15:45 | Abstract 301: Is the bar too high? Vitamin D Status of Children with Cystic Fibrosis at a Regional Centre in the North East of England – M. Brodlie (UK) |
| 15:45-16:00 | Abstract 276: Long-term pulmonary outcome in cystic fibrosis is not adversely affected in CF associated liver disease treated with UDCA – M. Kappler (DE) |
| 16:00-16:15 | Abstract 279: Growth and pulmonary outcomes during the first two years of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program – H. Lai (US) |
| 16:15-16:30 | Abstract 369: Developing a measure of eating attitudes and behaviours in cystic fibrosis – M. Bryon (UK) |
| 15:00-16:30 | Workshop 14 - New Developments in CF Cell Biology |
| Moderators: O. Zegarra-Moran (IT) / P. Quinton (US) | |
| 15:00-15:15 | Abstract 49: Probing the oligomeric state of CFTR – B. Berdiev (US) |
| 15:15-15:30 | Abstract 54: Proteomic identification of calumenin as a G551D - CFTR associated protein – P. Trouvé (FR) |
| 15:30-15:45 | Abstract 55: Molecular structure, packing and release of MUC2 with relevance to Cystic Fibrosis – H. Nilsson (SE) |
| 15:45-16:00 | Abstract 177: Expression of the NF-κB Inhibitor A20 Reflects CF Disease Severity – C. Kelly (UK) |
| 16:00-16:15 | Abstract 270: Neuroendocrine Characterization of the Intestine of F508 CFTR del mice – L. Hjelte (SE) |
| 16:15-16:30 | Abstract 57: Generation of new lung-specific tet-dependent activator mice for tight and quantitative control of conditional gene expression in the murine lung – J. Duerr (DE) |
| 15:00-16:30 | Workshop 15 - Early Colonisation – Where Does it Start? |
| Moderators: J. Mainz (DE) / H. Krogh Johansen (DK) | |
| 15:00-15:15 | Overview: Sinasal Niche for Lung Infection – H. Krogh Johansen (DK) |
| 15:15-15:30 | Abstract 152: Microevolution of the major common Pseudomonas aeruginosa clones C and PA14 in cystic fibrosis lungs – N. Cramer (DE) |
| 15:30-15:45 | Abstract 162: Identical obligate anaerobic bacteria in periodontal pockets and sputum of CF patients – D. Worlitzsch (DE) |
| 15:45-16:00 | Abstract 134: Molecular Characterization of Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Responsible for the First Infection in CF Patients – P. Cocchi (IT) |
| 16:00-16:15 | Abstract 125: Comparison of real time diagnostic chemistries to detect early and chronic Pseudomonas aeruginosa colonisation in cystic fibrosis patients – J. Fothergill (UK) |
| 16:15-16:30 | Abstract 102: Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus Colistin/Ciprofloxacin – F. Vermeulen (BE) |
| 15:00-16:30 | Workshop 16 - Physiotherapy - Associated Issues |
| Moderators: E. Main (UK) / I. Maguire (IE) | |
| 15:00-15:15 | Abstract 263: Prevalence and impact of urinary incontinence in adult men with cystic fibrosis – B. Button (AU) |
| 15:15-15:30 | Abstract 262: Non-Invasive (NI) Rehabilitation Program in CF Patients with Urinary Incontinence – M. Donà (IT) |
| 15:30-15:45 | Abstract 246: What is the level of understanding about Nebuliser Therapy in patients attending an Adult CF Clinic? – E. Lloyd (UK) |
| 15:45-16:00 | Abstract 244: Influence of Inhaled Hypertonic Saline (NaCl 6%) before or during Autogenic Drainage on Sputum Weight, Oxygen Saturation, Heart Frequency and Dyspnoea in Cystic Fibrosis Patients – H. Eyns (BE) |
| 16:00-16:15 | Abstract 260: Transcutaneous Electrical Nerve Stimulation (TENS) for acute lung pain in CF – K. Treacy (UK) |
| 16:15-16:30 | Abstract 208: Long-term Non-Invasive Ventilation in Adults with Cystic Fibrosis: Experience over Two Decades – W. Flight (UK) |
| 15:00-16:30 | Oral Poster Session 3 - CF Microbiology: Identification, Pathogenesis and Treatement |
| Moderators: P. Drevinek (CZ) / M. Tunney (UK) | |
| 15:00-15:10 | Abstract 154: Assessing the role of lysogenic bacteriophages in a cystic fibrosis epidemic strain of Pseudomonas aeruginosa – J. Fothergill (UK) |
| 15:10-15:20 | Abstract 168: The role of novel T helper cell subsets in Pseudomonas aeruginosa immunity – H. Bayes (UK) |
| 15:20-15:30 | Abstract 151: Sino-pulmonary pairs of mucoid and non-mucoid P. aeruginosa isolates from CF patients with chronic airways infection have similar gene expression profiles – O. Ciofu (DK) |
| 15:30-15:40 | Abstract 118: Microbial Diversity in the Cystic Fibrosis Lung – Assessing the Limitations of Current Diagnostic Microbiology and Antibiotic Susceptibility Profiling – S. Darch (UK) |
| 15:40-15:50 | Abstract 127: Array Tube Genotyping of Pseudomonas aeruginosa Isolates as A Strategy for Identifying Potential Emerging Transmissible Strains – A. Hall (UK) |
| 15:50-16:00 | Abstract 159: Proteomic analysis of the Burkholderia cepacia complex outer membrane proteins involved in adhesion to lung epithelial cells - M. Thomas (IE) |
| 16:00-16:10 | Abstract 136: Overlapping Genes as Molecular Markers for Identification of Bacteria: the Use of marC-hisH for the Identification of Burkholderia and Ralstonia – R. Fani (IT) |
| 16:10-16:20 | Abstract 161: Expression of virulence factors in MRSA isolates from CF sputum – S. McGrath(UK) |
| 16:20-16:30 | Abstract 100: Synergistic effects of a fosfomycin: tobramycin combination on CF pathogens grown aerobically and anaerobically – G. McCaughey (UK) |
| 16:30-17:00 | Coffee Break |
| 17:00-18:30 | Workshop 17 - Late Breaking Science |
| Moderators: L. Galietta (IT) / M. Mall (DE) | |
| 17:00-17:30 | Review from ECFS Basic Science conference - H. Cuppens (BE) |
| 17:30-18:00 | Deletion of the Ubiquitin Ligase Nedd4L in Lung Epithelia Causes Cystic Fibrosis-like Disease - D. Rotin (CA) |
| 18:00-18:30 | Efficacy and Safety of VX-770 in Subjects with CF and the G551D Mutation - S. Elborn (UK) |
| 17:00-18:30 | Workshop 18 - Inhaled Therapies |
| Moderators: M. Griese (DE) / L. Dupont (BE) | |
| 17:00-17:15 | Overview of Devices Used for Inhaled Antibiotic Delivery – M. Griese (DE) |
| 17:15-17:30 | Abstract 75: Small airways response to dornase alfa improves using controlled inhalation: a randomized controlled trial in cystic fibrosis patients – H. Tiddens (NL) |
| 17:30-17:45 | Abstract 82: Microbiological and Clinical Response to Tobramycin Inhalation Powder (TIP™) in CF Patients with Chronic Pseudomonas aeruginosa (Pa) Infection – D. Geller (US) |
| 17:45-18:00 | Abstract 356: Use Of Patient Monitoring Systems In Clinical Trials To Generate Objective Information On Patients’ Drug Adherence Of Inhaled Medications – C. Fuchs (DE) |
| 18:00-18:15 | Abstract 219: Monitoring Cystic Fibrosis patient´s adherence to nebulised antibiotics with the I-neb Adaptive Aerosol delivery (AAD) System – S. Gartner (ES) |
| 18:15-18:30 | Abstract 320: Longitudinal Adherence to Dornase Alfa (Pulmozyme): Association with Multiple Clinical Outcomes in Patients with Cystic Fibrosis – S. Warren (US) |
| 17:00-18:30 | Workshop 19 - Genetics - Challenges in Newborn Screening |
| Moderators: C. Castellani (IT) / K. Southern (UK) | |
| 17:00-17:15 | Abstract 19: Summary of the Simultaneous IRT/PAP/ST+DNA and IRT/DNA/IRT Newborn Screening Protocols in the Czech Republic – V. Krulisova (CZ) |
| 17:15-17:30 | Abstract 21: Improved Cut Off Combination for IRT and PAP in Newborn Screening for Cystic Fibrosis – J. Hammermann (DE) |
| 17:30-17:45 | Abstract 37: 15 years and two strategies for cystic fibrosis newborn screening in eastern saxony in Germany – J. Hammermann (DE) |
| 17:45-18:00 | Abstract 34: CF Newborn Screened False-Negative Cohort: A National Long Term Survey – A. Munck (FR) |
| 18:00-18:15 | Abstract 45: Meconium Ileus in Cystic Fibrosis Newborn Screening (CF NBS) – D. Sands (PL) |
| 18:15-18:30 | Abstract 371: Evidence of decline in CF incidence: study over a 40-year period – V. Scotet (FR) |
| 17:00-18:30 | Workshop 20 - Progress in Antimicrobial Therapies |
| Moderators: T. Pressler (DK) / J. Govan (UK) | |
| 17:00-17:15 | Abstract 94: A commercial garlic preparation exerts global inhibition of the quorum sensing (QS) system and virulence factor production of laboratory and clinical strains of Pseudomonas aeruginosa – M. Hurley (UK) |
| 17:15-17:30 | Abstract 68: Feasibility study of OSCN- and Lactoferrin (Meveol®) nebulization for cystic fibrosis patients – P. Bordeau (FR) |
| 17:30-17:45 | Abstract 86: Lung Function Improvement with Aztreonam 75 mg Powder and Solvent for Nebuliser Solution (AZLI) in a Single-Arm Extension of a Randomized Trial of Inhaled Antipseudomonal Antibiotics in Patients with Cystic Fibrosis (CF) and Pseudomonas aeruginosa Infection – B. Assael (IT) |
| 17:45-18:00 | Abstract 87: Effects of Inhaled MP-376 (AeroquinTM, Levofloxacin Inhalation Solution) on CF Patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) Lung Infection – P. Flume (US) |
| 18:00-18:15 | Abstract 217: A Multi-Cycle Open Label Study of Nebulized Liposomal Amikacin (Arikace™) in the Treatment of Cystic Fibrosis Patients with Chronic Pseudomonas Aeruginosa Lung Infection – P. Minic (RS) |
| 18:15-18:30 | Abstract 83: Sinonasal inhalation of Tobramycin in CF-patients with P.aeruginosa-colonization of the upper airways - results of a multicentric placebo controlled pilot study – J. Mainz (DE) |
| 17:00-18:30 | Workshop 21 - Nursing/Psychosocial Complex Case Presentations |
| Moderators: G. Latchford (UK) / V. Bregnballe (DK) | |
| 17:00-17:17 | Extreme Weight Loss: Anna 27 and Jennie 14 – M. Malmborg (SE) |
| 17:17-17:34 | Many Hands Make Light Work but Challenge Health Resources! – C. Dawson (UK) |
| 17:34-17:51 | Is it a Child Protection Case or is it not? That is the Question! – P. Titlbachova (UK) |
| 17:51-18:08 | Cystic Fibrosis: The Art of Adherence in Adults – M. Swallow (UK) |
| 18:08-18:25 | Should All Patients Have the Right to Self Administer Home Intravenous Antibiotics? – J. Dyer (UK) |
| 18:25-18:30 | Best Case Presentation Award |
| 17:00-18:30 | Physiotherapy Case Presentations |
| Moderators: B. Button (AU) / F. Van Ginderdeuren (BE) | |
| 17:00-17:17 | Munchausen CF? – R. Dentice (AU) |
| 17:17-17:34 | Airway Clearance Techniques in Severely Premature Baby with CF – J. Ballard (UK) |
| 17:34-17:51 | "I Don´t Do CF": Issues with Acceptance – G. Housley (UK) |
| 17:51-18:08 | High Frequency Chest Wall Oscillation (HFCWO) for Airways Clearance: An In“Vest”ment? – K. Treacy (UK) |
| 18:08-18:25 | Abstract 393: CPAP for atelectasis in bronchopulmonary – S. Gambazza (IT) |
| 18:25-18:30 | Best Case Presentation Award |
| Conference Dinner and Party | |
| 11 June | |
| 09:00-10:30 | Symposium 22 - Pancreatic Disease and CF |
| Moderators: M. Wilschanski (IL) / M. Cipolli (IT) | |
| 09:00-09:22 | Hereditary Pancreatitis – D. Whitcomb (US) |
| 09:22-09:44 | CFTR and Pancreatitis – P. Durie (CA) |
| 09:44-10:06 | Diagnosis and Treatment of PI – C. Taylor (UK) |
| 10:06-10:30 | Abstract 271: Pancreatic and Biliary Secretion Differ in Cystic Fibrosis and Wild-Type Pigs – A. Uc (US) |
| 09:00-10:30 | Symposium 23 - Latest Developments in CF Host Defense |
| Moderators: C. Moser (DK) / D. Hartl (DE) | |
| 09:00-09:22 | Epithelial Cells - C. Greene (IE) |
| 09:22-09:44 | Neutrophils – J. Nick (US) |
| 09:44-10:06 | Lymphocytes – C. Moser (DK) |
| 10:06-10:30 | Compartmentalisation of Infection/Inflammation in the Lung – S. Jeyaseelan (US) |
| 09:00-10:30 | Symposium 24 - Strategies towards Improving Transplantation Outcome in CF |
| Moderators: M. Ballmann (DE) / L. Dupont (BE) | |
| 09:00-09:22 | Expanding the Donor Pool: live donors – H. Date (JP) |
| 09:22-09:44 | Expanding the Donor Pool: Non Heart Beating donors – D. Van Raemdonck (BE) |
| 09:44-10:06 | Multi-Organ Transplantation in CF – L. Kessler (FR) |
| 10:06-10:30 | New Treatment Options for Chronic Rejection: Macrolides and More – J. Gottlieb (DE) |
| 09:00-10:30 | Symposium 25 - Parameters for Use in Registries |
| Moderators: M. Macek (CZ) / D. Peckham (UK) | |
| 09:00-09:22 | Validation and Comparison of Registry Data across Countries - E. McKone (IE) |
| 09:22-09:44 | How to measure Quality of Health Care in CF – H. Quinton (US) |
| 09:44-10:06 | Longitudinal Evaluation of Registry Data: Delta FEV1 - B. Wiedemann (DE) |
| 10:06-10:30 | Minimum data set for Emerging countries –A. Mehta / M Macek (CZ) |
| 09:00-10:30 | Symposium 26 - Delivering Best Practice |
| Moderators: V. Hall (UK) / K. Colpaert (BE) | |
| 09:00-09:22 | Consensus Guidelines and Best Practice in Managing CF - S. Madge (UK) |
| 09:22-09:44 | H-IVAT – C. Glasscoe (UK) |
| 09:44-10:06 | Inhalation Therapies – R. Dentice (AU) |
| 10:06-10:30 | Psychosocial Impact on Caring at end of Life – C. Kugler (DE) |
| 10:30-11:00 | Coffee Break |
| 11:00-12:30 | Plenary - Cystic Fibrosis 2011 |
| Moderators: S. Elborn (UK) / M. Ballmann (DE) | |
| Models of Inflammation: From Bench to Bedside - M. Mall (DE) | |
| Genotype-Phenotype in CF: Implications in CF Care - P. Durie (CA) | |
| ECFS President Address + ECFS Projects – S. Elborn (UK) | |
| 12:30-13:00 | Closing Ceremony |
Printer-friendly version